Evaluation of Genomic Applications in Practice and Prevention (EGAPP)
ShareCompartir
This website is archived for historical purposes and is no longer being maintained or updated.
The EGAPP Working Group was established in 2005 to support the development of a systematic process for assessing the available evidence regarding the validity and utility of rapidly emerging genetic tests for clinical practice. This independent, multidisciplinary panel prioritizes and selects tests, reviews CDC-commissioned evidence reports and other contextual factors, highlights critical knowledge gaps, and provides guidance on appropriate use of genetic tests in specific clinical scenarios.
What's New
-
Article:
The EGAPP Working Group has published a new article entitled “The EGAPP Initiative: Lessons Learned”
-
Article[PDF 656 KB]:
The EGAPP Working Group has published a new article entitled “Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies” [PDF 656 KB] in collaboration with Kaiser Permanente Center for Health Research.
EGAPP Recommendations
-
Colorectal Cancer:
Can testing of tumor tissue for mutations in EGFR pathway downstream effector genes…
-
Cardiovascular Health:
Outcomes of Genetic Testing in Adults with a History of Venous Thromboembolism
-
Cardiovascular Health:
Genomic profiling to assess cardiovascular risk to improve cardiovascular health…
- Page last reviewed: September 22, 2016 (archived document)
- Content source: